Altimmune, Inc. (ALT)
NASDAQ: ALT · Real-Time Price · USD
3.080
+0.070 (2.33%)
At close: Aug 7, 2026, 4:00 PM EDT
3.070
-0.010 (-0.32%)
After-hours: Aug 7, 2026, 7:53 PM EDT
Altimmune Employees
Altimmune had 57 employees as of December 31, 2025. The number of employees decreased by 2 or -3.39% compared to the previous year.
Employees
57
Change (1Y)
-2
Growth (1Y)
-3.39%
Revenue / Employee
$632
Profits / Employee
-$1,597,912
Market Cap
598.98M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 57 | -2 | -3.39% |
| Dec 31, 2024 | 59 | 0 | - |
| Dec 31, 2023 | 59 | 7 | 13.46% |
| Dec 31, 2022 | 52 | 5 | 10.64% |
| Dec 31, 2021 | 47 | 4 | 9.30% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| MiMedx Group | 808 |
| Arvinas | 246 |
| CorMedix | 191 |
| ARS Pharmaceuticals | 159 |
| Verastem | 102 |
| Silence Therapeutics | 88 |
| Tectonic Therapeutic | 60 |
| Contineum Therapeutics | 51 |
ALT News
- 2 days ago - Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026 - GlobeNewsWire
- 4 days ago - Altimmune initiates PERFORMA trial - TheFly
- 4 days ago - Altimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH - GlobeNewsWire
- 10 days ago - Barclays says trial data highlights meaningful opportunity for Altimmune in AUD - TheFly
- 10 days ago - H.C. Wainwright sees ‘clear Phase 2 win’ for Altimmune - TheFly
- 10 days ago - Leerink remains bullish on Altimmune following ‘positive’ AUD trial results - TheFly
- 10 days ago - Altimmune Transcript: Study result - Transcripts
- 10 days ago - Altimmune Press release: Study result - Filings